Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S.P. Vermaat, Olivier Casasnovas, Nada Hamad, Josée M. Zijlstra, Sameer Bakhshi, Reda Bouabdallah, Sylvain Choquet, Ronit Gurion, Brian Hill, Ulrich Jaeger, Juan Manuel Sancho, Michael Schuster, Catherine Thieblemont, Fátima De la Cruz, Miklos EgyedSourav Mishra, Fritz Offner, Theodoros P. Vassilakopoulos, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Kelly Corona, Jean Richard Saint-Martin, Hua Chang, Yosef Landesman, Anita Joshi, Hongwei Wang, Jatin Shah, Sharon Shacham, Michael Kauffman, Eric Van Den Neste, Miguel A. Canales

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences